A retrospective descriptive study of oral azole antifungal agents in patients with patch test–negative head and neck predominant atopic dermatitis - 14/08/14
Abstract |
Background |
Head and neck dermatitis is a subtype of atopic dermatitis driven by Malassezia yeast.
Objective |
We sought to evaluate the response of these patients to systemic azole antifungals.
Methods |
We queried the electronic medical records from our institution for patients that were referred for allergy patch testing, were ultimately given the diagnosis of head and neck dermatitis, and were treated with oral azole antifungals over a 2-year period.
Results |
Twenty-four patients met inclusion criteria and were analyzed. Most patients noted their characteristic flare beginning during their teenage, young adult, or adult years. All were noted to have some involvement of the head and neck, and 17 responded to treatment. The mean time taking an azole antifungal medication was 8 months, with a mean overall follow-up of 10 months.
Limitations |
This was a retrospective descriptive study, from a single institution, of a limited number of patients, and did not use a validated scoring system.
Conclusion |
Itraconazole and other azole antifungals were an effective treatment for more than two-thirds of adult patients with head and neck predominant atopic dermatitis.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, contact dermatitis, eczema, fluconazole, head and neck dermatitis, itraconazole, ketoconazole, Malassezia, occupational dermatitis, seborrheic dermatitis
Abbreviations used : AD, APT, HND, SD, SPT
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 71 - N° 3
P. 480-483 - septembre 2014 Retour au numéro
Article précédent
- Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: Defining a niche for these low toxicity agents
- Morgan McCarty, David Fivenson
- Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study
- D.S. Krupashankar, Sunil Dogra, Mahendra Kura, Abir Saraswat, Leelavathy Budamakuntla, T.K. Sumathy, Radha Shah, M.G. Gopal, T. Narayana Rao, C.R. Srinivas, Ramesh Bhat, Narendra Shetty, G. Manmohan, Kotla Sai Krishna, Dalavoi Padmaja, Dasiga Venkata Subrahmanya Pratap, Vijay Garg, Sandesh Gupta, Neeraj Pandey, Uday Khopkar, Enrique Montero, M.S. Ramakrishnan, Pradip Nair, Prasanna C. Ganapathi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?